Vital signs: overdoses of prescription opioid pain relievers and other drugs among women--United States, 1999-2010

Centers for Disease Control and Prevention (CDC), Centers for Disease Control and Prevention (CDC)

Abstract

Background: Overdose deaths have increased steadily over the past decade. This report describes drug-related deaths and emergency department (ED) visits among women.

Methods: CDC analyzed rates of fatal drug overdoses and drug misuse- or abuse-related ED visits among women using data from the National Vital Statistics System (1999-2010) and the Drug Abuse Warning Network (2004-2010).

Results: In 2010, a total of 15,323 deaths among women were attributed to drug overdose, a rate of 9.8 per 100,000 population. Deaths from opioid pain relievers (OPRs) increased fivefold between 1999 and 2010 for women; OPR deaths among men increased 3.6 times. In 2010, there were 943,365 ED visits by women for drug misuse or abuse. The highest ED visit rates were for cocaine or heroin (147.2 per 100,000 population), benzodiazepines (134.6), and OPR (129.6). ED visits related to misuse or abuse of OPR among women more than doubled between 2004 and 2010.

Conclusions: Although more men die from drug overdoses than women, the percentage increase in deaths since 1999 is greater among women. More women have died each year from drug overdoses than from motor vehicle-related injuries since 2007. Deaths and ED visits related to OPR continue to increase among women. The prominent involvement of psychotherapeutic drugs, such as benzodiazepines, among overdoses provides insight for prevention opportunities.

Implications for public health practice: Health-care providers should follow guidelines for responsible prescribing, including screening and monitoring for substance abuse and mental health problems, when prescribing OPR. Health-care providers who treat women for pain should use their state's prescription drug monitoring program and regularly screen patients for psychological disorders and use of psychotherapeutic drugs, with or without a prescription.

Figures

FIGURE 1
FIGURE 1
Age-adjusted death rates* for drug overdose deaths among women — National Vital Statistics System, United States, 2009–2010 * Deaths per 100,000 population; age-adjusted to the 2000 U.S. standard population using the bridge-race estimates.
FIGURE 2
FIGURE 2
Crude rates* for drug overdose deaths and drug misuse- or abuse-related emergency department (ED) visits among women, by select drug class — National Vital Statistics System and Drug Abuse Warning Network, United States, 2004–2010 * Scales differ for deaths and emergency department visits.

References

    1. CDC. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR. 2011;60:1487–92.
    1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309:657–9.
    1. Jones CM. Frequency of prescription pain reliever nonmedical use: 2002–2003 and 2009–2010. Arch Intern Med. 2012;172:1265–7.
    1. Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993–2009. PLoS One. 2013;8(2):e54496.
    1. CDC. Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004–2008. MMWR. 2010;59:705–9.
    1. Campbell CI, Weisner C, Leresche L, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health. 2010;100:2541–7.
    1. Williams RE, Sampson TJ, Kalilani L, Wurzelmann JI, Janning SW. Epidemiology of opioid pharmacy claims in the United States. J Opioid Manag. 2008;4:145–52.
    1. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL., 3rd Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10:447–85.
    1. Unruh AM. Gender variations in clinical pain experience. Pain. 1996;65:123–67.
    1. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613–20.
    1. Saunders KW, Von Korff M, Campbell CI, et al. Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors. J Pain. 2012;13:266–75.
    1. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.
    1. Fillingim RB, Ness TJ, Glover TL, et al. Morphine responses and experimental pain: sex differences in side effects and cardiovascular responses but not analgesia. J Pain. 2005;6:116–24.
    1. Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) 51. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2009. Substance abuse treatment: addressing the specific needs of women. Available at .
    1. Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. J Addict Dis. 2010;29:127–38.
    1. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307:1934–40.
    1. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314.e1–11.
    1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–30.
    1. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non-medical use of prescription opioids: results from a national US survey. Addiction. 2008;103:258–68.
    1. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E. The validity of race and Hispanic origin reporting on death certificates in the United States. Vital Health Stat 2. 2008;148:1–23.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj